Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 465-471 , November 2006

Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results

  • Kimberly A. Roehl, M.P.H.

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63105, USA
    • ,
  • Scott E. Eggener, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    • ,
  • Stacy Loeb, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    • ,
  • Norm D. Smith, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    • ,
  • Jo Ann V. Antenor, M.P.H.

      Affiliations

    • Department of Neurology, Washington University School of Medicine, St. Louis, MO 63105, USA
    • ,
  • William J. Catalona, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-695-4471; fax: +1-312-695-1482.

Received 17 August 2005 ,Revised 29 November 2005 ,Accepted 30 November 2005.

References 

  1. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol. 2005;174:121–125
  2. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer–Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024
  3. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–170
  4. Paquette EL, Sun L, Paquette LR, et al. Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing. Urology. 2002;60:756–759
  5. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  6. Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int. 2002;90:686–693
  7. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4:473–485
  8. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. Cancer. 1997;80:1852–1856
  9. Weinmann S, Richert-Boe KE, Van Den Eeden SK, et al. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: A case-control study. Epidemiology. 2005;16:367–376
  10. Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: A population-based case-control study. Urology. 1998;52:173–179
  11. American Cancer Society. Cancer facts and figures 2005. Atlanta, (GA): American Cancer Society; 2005;
  12. Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740
  13. Shaw PA, Etzioni R, Zeliadt SB, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160:1059–1069
  14. Perron L, Moore L, Bairati I, et al. PSA screening and prostate cancer mortality. CMAJ. 2002;166:586–591
  15. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417–424
  16. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990
  17. D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–1383
  18. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984
  19. Ohori M, Wheeler TM, Dunn JK, et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994;152:1714–1720
  20. Krumholtz JS, Carvalhal GF, Ramos CG, et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 2002;60:469–473
  21. Pinsky PF, Andriole GL, Kramer BS, et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2005;173:746–750

☆ Supported by a grant from Beckman Coulter Incorporated, Fullerton, CA, and by the Urological Research Foundation.

PII: S1078-1439(05)00305-4

doi: 10.1016/j.urolonc.2005.11.039

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 465-471 , November 2006

Article Tools

* Image Usage & Resolution